87 ECG changes in Fabry disease 19. Morimoto, S., et al., Characteristics of the Electrocardiogram in Japanese Fabry Patients Under Long-Term Enzyme Replacement Therapy. Frontiers in Cardiovascular Medicine, 2021. 7. 20. Nordin, S., et al., Proposed Stages of Myocardial Phenotype Development in Fabry Disease. JACC Cardiovasc Imaging, 2018. 21. Vitale, G., et al., Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. Heart, 2021: p. heartjnl-2020-318271. 22. Arends, M., et al., Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet, 2018. 55(5): p. 351-358. 23. El Dib, R., et al., Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS One, 2017. 12(3): p. e0173358. 24. Stronks, K., et al., Unravelling the impact of ethnicity on health in Europe: the HELIUS study BMC Public Health, 2013. 13: p. 402. 25. Snijder, M.B., et al., Cohort profile: the Healthy Life in an Urban Setting (HELIUS) study in Amsterdam, The Netherlands. BMJ Open, 2017. 7(12): p. e017873. 26. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama, 2013. 310(20): p. 2191-4. 27. van Bemmel, J.H., J.A. Kors, and G. van Herpen, Methodology of the modular ECG analysis system MEANS. Methods Inf Med, 1990. 29(4): p. 346-53. 28. Schielzeth, H., et al., Robustness of linear mixed-effects models to violations of distributional assumptions. Methods in Ecology and Evolution, 2020. 11(9): p. 1141-1152. 29. Vedder, A.C., et al., Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One, 2007. 2(7): p. e598. 30. Mason, J.W., et al., Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J Electrocardiol, 2007. 40(3): p. 228-34. 31. Kardys, I., et al., Spatial QRS-T angle predicts cardiac death in a general population. European Heart Journal, 2003. 24(14): p. 1357-1364. 32. Kors, J.A., et al., T axis as an indicator of risk of cardiac events in elderly people. The Lancet, 1998. 352(9128): p. 601-605. 33. Azevedo, O., et al., Fabry Disease and the Heart: A Comprehensive Review. Int J Mol Sci, 2021. 22(9). 34. Namdar, M., et al., PQ interval in patients with Fabry disease. Am J Cardiol, 2010. 105(5): p. 753-6. 35. Straus, S.M., et al., Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol, 2006. 47(2): p. 362-7. 36. Salazar, M.F., et al., Spectral Turbulence Analysis: A Valuable Method for the Prediction of Cardiac Events in Elderly Patients With Intraventricular Conduction Abnormalities. Am J Geriatr Cardiol, 1998. 7(4): p. 15-28. 37. Magnani, J.W., et al., P wave duration is associated with cardiovascular and all-cause mortality outcomes: the National Health and Nutrition Examination Survey. Heart rhythm, 2011. 8(1): p. 93-100. 3
RkJQdWJsaXNoZXIy MTk4NDMw